22.20Open21.20Pre Close2 Volume15 Open Interest60.00Strike Price4.29KTurnover98.37%IV2.95%PremiumDec 20, 2024Expiry Date18.39Intrinsic Value100Multiplier20DDays to Expiry2.31Extrinsic Value100Contract SizeAmericanOptions Type0.8991Delta0.0097Gamma4.02Leverage Ratio-0.0847Theta0.0285Rho3.61Eff Leverage0.0327Vega
GeneDx Holdings Stock Discussion
Now for the big November update! Here are some stocks with upcoming earnings that I think have great potential to grow. Make sure to do your own research before jumping in! Let’s get it!
(E = Entry, T= Target)
$Jakks Pacific (JAKK.US)$ E = 28 - 28.8 T = 33.5 - 34
A mul...
The risk level for GeneDx Holdings Corp. is high due to multiple factors that elevate volatility and potential drawdowns. The company's inability to maintain profitability and high debt levels relative to cash position are concerning for long-term financial stability. GeneDx's impressive short-term stock surge, while promising, rests heavily on recent positive news, making the price susceptible to sudden reversals if sentiments shift. Moreover, the stock's failure to e...
A quick recap for the month ending April 30, 2024.
Ten stocks with >300% YTD
$Swvl Holdings (SWVL.US)$718.40%
$Root Inc (ROOT.US)$564.60%
$Elevation Oncology (ELEV.US)$561.08%
$JanOne (JAN.US)$554.05%
$GeneDx Holdings (WGS.US)$520.71%
$Corbus Pharmaceuticals (CRBP.US)$513.25%
$AGBA Group (AGBA.US)$482.90%
$Janux Therapeutics (JANX.US)$431.22%
$Dave Inc (DAVE.US)$4...
over 18-19 may be possible to fill gap
NEWS
GeneDx Announces Partnership with Komodo Health to Expand Access to World’s Largest Rare Disease Dataset
No comment yet